dpp 4 inhibitors vs glp 1 Clinical Use of DPP-4 fig2.gif

Efficacy is on par with injectable semaglutide with up to 1.7% reduction on the highest dose, and change in fasting glucose from -30 to -42mg/dl which is a significant improvement in glycemia

Physiology, pharmacology and clinical relevance of GLP-1 GLP-1 is a peptide hormone produced within the L cells of the intestine

GLP-1 receptor agonists, SGLT2 inhibitors and DPP-4 inhibitors GLP-1 receptor agonists, sodium glucose co-transporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors reduce the risk of MACE compared to placebo

Tran will help monitor weight loss progress and adjust dosages if necessary

10.1101/lm.037267.114 44 GejlM.GjeddeA.EgefjordL.MollerA.HansenS